Toronto, Ontario November 28, 2025 (CSE: AYUR, OTCQB: AYURF) (“ayurkann” or “Company“” is pleased to announce its financial and operating results for the three months ended September 30, 2025, the highlights of which are included in this press release. All figures are in Canadian dollars. The Company's complete unaudited condensed interim consolidated financial statements for the three months ended September 30, 2025, as well as management's accompanying discussion and analysis, can be obtained by visiting the Company's website at www.ayurcann.com and his profile on SEDAR+ at www.sedarplus.ca.
Key indicators for the first quarter of 2026: stable performance
Income: Ayurkann created US$14,638,697 gross revenue with gross profit of $2,236,343 and a healthy gross margin of 26% in the first quarter of 2026 (compared to gross revenue of $14,657,485 with gross profit of $3,321,974 and a gross margin of 40% in the first quarter of 2025), reflecting continued robust demand for our expanding product categories and successful national distribution efforts.
Leadership by market share: Ayurkann is now recognized Top three largest vape manufacturers in Ontario by volumeWith 5% share of the national vape market And 7% share in Ontariohighlighting our dominance in one of Canada's fastest growing categories.1
Highly productive operator
Operational discipline: Ayurcann has established itself as one of Canada's most efficient and reliable cannabis producers, consistently delivering results, quality and on-time delivery.
Accelerating Innovation: In the last six months alone, the Company has implemented 30 new storage units among leading consumer categories – vapes, pre-rolls and concentrates – driving increased shelf presence and broader retail adoption.
Engines of sustainable growth
Ayurcann's leadership in the vape segment provides a strong platform for growth as we aggressively scale production of high-demand pre-rolls and concentrates with distribution to multiple licensed retailers across Canada. Ayurcann continues to strengthen its position as a trusted national supplier to both retailers and consumers.
For more information contact:
Igal Sudman, General Director
Ayurkann Holdings Corp.
Tel: 905-492-3322
E-mail: [email protected]
Investor Relations:
E-mail: [email protected]
About Ayurkanna:
Ayurcann is a leading licensed cannabis producer focusing on the Canadian recreational market, offering proprietary products and formulations including Vape Carts, pre-rolls, concentrates and extracts.
For more information about Ayurkanna visit www.ayurcann.com and his profile on SEDAR+ at www.sedarplus.ca.
Cautionary Note Regarding Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of applicable securities laws. All statements contained herein that are not expressly historical in nature may constitute forward-looking statements. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “strategy”, “expects” or “does not expect”, “intends”, “continues”, “expects” or “does not expect”, or “believes”, or variations of such words and phrases, or may contain statements that certain actions, events or results “will be taken”, “will begin” or “will be launched”, “will include”, “will allow”, “will be done”, “will continue”, “will occur” or “will be achieved”. Forward-looking information and forward-looking statements contained herein include, but are not limited to, statements regarding: The Company achieves its objectives and strategic directions set forth herein; The company continues to grow, expand and benefit from its earnings, sales and growth trajectory; future growth of the cannabis industry; The Company is well positioned for long-term growth, profitability, success, productivity, value creation and shareholder returns; The company enters the high-demand pre-roll and concentrate market; the Company's entry into new markets, strengthening partnerships with retailers and increasing the range of products throughout the country; and the Company continues to be a leading player in the cannabis industry.
The forward-looking information in this press release is based on certain assumptions and expected future events, as follows: The Company will focus on custom pharmaceutical grade processes and products for adult use and the medical cannabis industry in Canada; The Company will be able to achieve its objectives and strategic directions set forth herein; The Company will be able to continue to grow, expand and benefit from its revenues, sales and growth trajectory; the cannabis industry will continue to grow; The Company will continue to achieve long-term growth, profitability, success, productivity, value creation and shareholder returns; The company will produce in-demand pre-rolls and concentrates; The company will enter new markets, strengthen retail partnerships and increase its product range across the country; and the Company will continue to be a leading player in the cannabis industry.
These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including, but not limited to: the Company's failure to achieve its objectives and strategic directions set forth herein; the Company's inability to continue to grow, expand and/or benefit from its revenues, sales and/or growth trajectory; cannabis industry growth declines and/or plateaus; Company growth, profitability, productivity, value creation and/or shareholder returns decline and/or plateau; the Company's inability to scale to produce high-demand pre-rolls and/or concentrates; the Company's inability to expand into new markets, strengthen retail partnerships and/or increase product offerings nationwide; and The Company is not a leading player in the cannabis industry.
Readers are cautioned that the above list is not exhaustive. Readers are also cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations on which they are based will occur. Such information, although believed to be reasonable by management at the time it was prepared, may prove to be incorrect and actual results may differ materially from those anticipated. Actual results and developments may differ materially from those contemplated in these statements. Although the Company believes that the expectations reflected in these statements are reasonable, such statements are based on expectations, factors and assumptions regarding future events that may prove to be inaccurate and are subject to numerous risks and uncertainties, some of which are beyond the Company's control, including, without limitation, the risk factors discussed under “Risk Factors” in the Company's public disclosure and elsewhere in this press release, as such factors may be updated from time to time in our periodic filings available at www.sedarplus.cawhich factors are incorporated herein by reference. The forward-looking statements contained in this press release are expressly qualified by this cautionary statement and reflect the Company's expectations as of the date of this press release and are subject to subsequent change. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results or otherwise, or to explain any material differences between subsequent actual events and such forward-looking information, except as required by applicable law.
Neither the Canadian Securities Exchange nor its regulatory services provider has reviewed or accepts responsibility for the adequacy or accuracy of this release.
1 Based on Hifyre IQTM report as of September 30, 2025.
